URGN

+ Watchlist + Portfolio

UroGen Pharma Ltd.

GridBrain — Sign in

GridSentinel — Sign in

GridAegis — Sign in

Key Metrics

Previous Close: $50.29
52-Week Range: $15.86 – $50.81
Market Cap: $2.29B
P/E (TTM): —
EPS (TTM): -1.97
Dividend Yield: —

Advanced Metrics

Price/Book: —
PEG Ratio: —
Return on Equity: —
Return on Assets: -18.06%
Gross Margin: 90.84%
Operating Margin: 0.15%
Profit Margin: -51.73%
Current Ratio: 3.80
Debt/Equity: —
Total Debt: $196.13M
Free Cash Flow: $-106.98M
Revenue Growth: 199.20%
Earnings Growth: —
Enterprise Value: $2.55B

URGN Income statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Revenue	$64.36M	$82.71M	$90.40M	$109.79M
Cost of Revenue	$7.65M	$9.36M	$8.88M	$12.45M
Gross Profit	$56.70M	$73.35M	$81.52M	$97.34M
Research & Development	$52.91M	$45.61M	$57.15M	$67.11M
Selling, General & Admin	$82.84M	$93.27M	$121.15M	$155.10M
Operating Expenses	$135.74M	$138.89M	$178.30M	$222.20M
Operating Income	-$79.04M	-$65.54M	-$96.78M	-$124.86M
EBITDA	-$97.77M	-$81.90M	-$110.33M	-$135.66M
Pretax Income	-$108.03M	-$98.32M	-$124.04M	-$153.42M
Income Tax	$1.75M	$3.92M	$2.83M	$78.00K
Net Income	-$109.78M	-$102.24M	-$126.87M	-$153.49M
Diluted EPS	-4.79	-3.55	-2.96	-3.19
Diluted Shares	22.81M	28.83M	42.88M	48.12M

URGN Balance Sheet statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Cash & Equivalents	$55.41M	$95.00M	$171.99M	$110.75M
Receivables	$12.70M	$15.44M	$20.30M	$33.08M
Inventory	$4.33M	$5.67M	$9.23M	$16.46M
Current Assets	$128.91M	$169.19M	$276.13M	$186.02M
Total Assets	$135.62M	$178.31M	$285.71M	$200.46M
Current Liabilities	$23.92M	$31.21M	$45.95M	$46.42M
Long-Term Debt	$97.54M	$98.55M	$121.73M	$122.21M
Total Debt	$99.12M	$99.39M	$123.39M	$128.33M
Total Liabilities	$224.98M	$243.52M	$294.51M	$305.93M
Retained Earnings	-$577.10M	-$679.35M	-$806.22M	-$959.72M
Shareholders' Equity	-$89.36M	-$65.21M	-$8.80M	-$105.47M
Working Capital	$104.99M	$137.97M	$230.19M	$139.61M
Net Debt	$42.13M	$3.55M	—	$11.46M

URGN Cash Flow statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Operating Cash Flow	-$87.56M	-$76.38M	-$96.77M	-$162.44M
Capital Expenditure	-$254.00K	-$194.00K	-$295.00K	-$289.00K
Free Cash Flow	-$87.81M	-$76.57M	-$97.06M	-$162.73M
Depreciation & Amortisation	$1.82M	$1.71M	$1.19M	$2.41M
Stock-Based Compensation	$10.58M	$9.34M	$13.11M	$11.96M
Investing Cash Flow	$1.06M	-$953.00K	-$20.61M	$61.56M
Financing Cash Flow	$97.13M	$116.93M	$194.62M	$39.92M
Net Change in Cash	$10.63M	$39.60M	$77.24M	-$60.97M

URGN Income statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Revenue	$20.25M	$24.21M	$27.48M	$37.84M	$50.96M
Cost of Revenue	$2.33M	$3.55M	$3.28M	$3.29M	$4.14M
Gross Profit	$17.92M	$20.66M	$24.20M	$34.55M	$46.82M
Research & Development	$19.87M	$18.91M	$14.01M	$14.31M	$15.60M
Selling, General & Admin	$34.97M	$43.20M	$37.58M	$39.35M	$51.49M
Operating Expenses	$54.84M	$62.11M	$51.59M	$53.66M	$67.08M
Operating Income	-$36.91M	-$41.45M	-$27.39M	-$19.11M	-$20.26M
EBITDA	-$38.89M	-$44.20M	-$30.39M	-$22.19M	-$23.51M
Pretax Income	-$43.45M	-$48.92M	-$34.40M	-$26.64M	-$28.35M
Income Tax	$392.00K	$1.01M	-$1.05M	-$275.00K	-$4.77M
Net Income	-$43.84M	-$49.94M	-$33.35M	-$26.36M	-$23.57M
Diluted EPS	-0.92	-1.05	-0.69	-0.54	-0.47
Diluted Shares	47.42M	47.74M	48.06M	49.23M	50.18M

URGN Balance Sheet statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Cash & Equivalents	$104.03M	$92.90M	$90.04M	$110.75M	$109.97M
Receivables	$19.64M	$19.65M	$19.70M	$33.08M	$55.41M
Inventory	$7.59M	$7.13M	$8.34M	$16.46M	$20.92M
Current Assets	$237.18M	$196.87M	$168.55M	$186.02M	$237.46M
Total Assets	$247.62M	$208.72M	$185.05M	$200.46M	$253.69M
Current Liabilities	$42.00M	$47.55M	$42.24M	$46.42M	$50.63M
Long-Term Debt	$122.11M	$122.51M	$122.11M	$122.21M	$189.53M
Total Debt	$124.95M	$125.92M	$128.35M	$128.33M	$195.18M
Total Liabilities	$294.08M	$302.09M	$300.45M	$305.93M	$377.94M
Retained Earnings	-$850.07M	-$900.00M	-$933.35M	-$959.72M	-$983.29M
Shareholders' Equity	-$46.46M	-$93.38M	-$115.41M	-$105.47M	-$124.25M
Working Capital	$195.18M	$149.32M	$126.30M	$139.61M	$186.83M
Net Debt	$18.07M	$29.60M	$32.07M	$11.46M	$79.56M

URGN Cash Flow statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Operating Cash Flow	-$42.02M	-$39.83M	-$42.27M	-$38.33M	-$45.32M
Capital Expenditure	-$44.00K	-$141.00K	-$87.00K	-$17.00K	-$54.00K
Free Cash Flow	-$42.07M	-$39.97M	-$42.36M	-$38.34M	-$45.37M
Depreciation & Amortisation	$497.00K	$596.00K	$639.00K	$679.00K	$652.00K
Stock-Based Compensation	$3.07M	$2.73M	$3.03M	$3.13M	$4.63M
Investing Cash Flow	-$25.96M	$28.41M	$31.40M	$27.72M	-$20.69M
Financing Cash Flow	$34.00K	$296.00K	$8.27M	$31.32M	$65.20M
Net Change in Cash	-$67.95M	-$11.12M	-$2.60M	$20.71M	-$800.00K

Market Snapshot

About

UroGen Pharma is a biopharmaceutical company developing treatments for urological cancers and diseases. The company specializes in RTGel technology, a proprietary sustained-release hydrogel formulation that enables prolonged exposure of urological tissues to therapeutic agents. UroGen focuses on bladder and upper urinary tract cancers.